Michael Chan to Survival Analysis
This is a "connection" page, showing publications Michael Chan has written about Survival Analysis.
Connection Strength
0.967
-
Hughes RT, Masters AH, McTyre ER, Farris MK, Chung C, Page BR, Kleinberg LR, Hepel J, Contessa JN, Chiang V, Ruiz J, Watabe K, Su J, Fiveash JB, Braunstein S, Chao S, Attia A, Ayala-Peacock DN, Chan MD. Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience. Int J Radiat Oncol Biol Phys. 2019 08 01; 104(5):1091-1098.
Score: 0.158
-
Ayala-Peacock DN, Attia A, Braunstein SE, Ahluwalia MS, Hepel J, Chung C, Contessa J, McTyre E, Peiffer AM, Lucas JT, Isom S, Pajewski NM, Kotecha R, Stavas MJ, Page BR, Kleinberg L, Shen C, Taylor RB, Onyeuku NE, Hyde AT, Gorovets D, Chao ST, Corso C, Ruiz J, Watabe K, Tatter SB, Zadeh G, Chiang VLS, Fiveash JB, Chan MD. Prediction of new brain metastases after radiosurgery: validation and analysis of performance of a multi-institutional nomogram. J Neurooncol. 2017 Nov; 135(2):403-411.
Score: 0.141
-
Shenker RF, McTyre ER, Ruiz J, Weaver KE, Cramer C, Alphonse-Sullivan NK, Farris M, Petty WJ, Bonomi MR, Watabe K, Laxton AW, Tatter SB, Warren GW, Chan MD. The Effects of smoking status and smoking history on patients with brain metastases from lung cancer. Cancer Med. 2017 May; 6(5):944-952.
Score: 0.138
-
McTyre ER, Johnson AG, Ruiz J, Isom S, Lucas JT, Hinson WH, Watabe K, Laxton AW, Tatter SB, Chan MD. Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy. Neuro Oncol. 2017 04 01; 19(4):558-566.
Score: 0.137
-
Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, Chan MD. Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget. 2015 Aug 07; 6(22):18945-55.
Score: 0.122
-
Liu A, Kuhn EN, Lucas JT, Laxton AW, Tatter SB, Chan MD. Gamma Knife radiosurgery for meningiomas in patients with neurofibromatosis Type 2. J Neurosurg. 2015 Mar; 122(3):536-42.
Score: 0.118
-
Wu K, Fukuda K, Xing F, Zhang Y, Sharma S, Liu Y, Chan MD, Zhou X, Qasem SA, Pochampally R, Mo YY, Watabe K. Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer. J Biol Chem. 2015 Apr 10; 290(15):9842-54.
Score: 0.030
-
Neal MT, Chan MD, Lucas JT, Loganathan A, Dillingham C, Pan E, Stewart JH, Bourland JD, Shaw EG, Tatter SB, Ellis TL. Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg. 2014 Dec; 82(6):1250-5.
Score: 0.026
-
Kuhn EN, Chan MD, Tatter SB, Ellis TL. Gamma knife stereotactic radiosurgery for radiation-induced meningiomas. Stereotact Funct Neurosurg. 2012; 90(6):365-9.
Score: 0.025
-
Loganathan AG, Chan MD, Alphonse N, Peiffer AM, Johnson AJ, McMullen KP, Urbanic JJ, Saconn PA, Bourland JD, Munley MT, Shaw EG, Tatter SB, Ellis TL. Clinical outcomes of brain metastases treated with Gamma Knife radiosurgery with 3.0?T versus 1.5?T MRI-based treatment planning: have we finally optimised detection of occult brain metastases? J Med Imaging Radiat Oncol. 2012 Oct; 56(5):554-60.
Score: 0.025
-
Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, Urbanic JJ, McMullen KP, Shaw EG, Tatter SB, Ellis TL. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg. 2012 May; 116(5):978-83.
Score: 0.024
-
Harris S, Chan MD, Lovato JF, Ellis TL, Tatter SB, Bourland JD, Munley MT, deGuzman AF, Shaw EG, Urbanic JJ, McMullen KP. Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):e53-9.
Score: 0.024